With Friday’s ruling by New Jersey District Judge Zahid Quraishi, Novartis joins a growing list of pharmaceutical companies ...

Novartis has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by ...

The Committee for Medicinal Products for Human Use adopted a positive opinion for NVS' Kisqali to help reduce the risk of recurrence in people with HR+/HER2- early breast cancer.

As a host of generics circle the gates, Novartis has lost another bid to waylay MSN Pharmaceuticals’ copycat of the Swiss ...

Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. | Novartis is paying ...

BP’s program includes a novel PSMA-binding molecule that may be a potential next-generation radioligand therapy (RLT) for prostate cancer and is currently being studied in two investigator-initiated ...

Novartis has assured that steps are being taken to ensure the adequate supply of Desferal, a drug crucial for treating iron ...

肺移植行业报告对全球范围内重点竞争企业进行详尽分析，其中包括Terumo, Pfizer, Sanofi, Cleveland Clinic, Astellas Pharma, Novartis, Roche, Temple Lung Center, ...

Novartis has terminated a phase 2 trial of its SMURF1 inhibitor LTP001 in idiopathic pulmonary fibrosis (IPF) but will ...

Novartis halted its Phase II IPF trial for LTP001, citing non-safety reasons. This move aligns with its strategy to ...

Novartis announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion ...

Novartis said the European Medicines Agency has recommended its Kisqali cancer drug for market authorization. The drugmaker said Friday that the EMA's Committee for Medicinal Products for Human Use ...